The Medically Reproducing Bariatric Surgery (MRB) II Study

NCT06363747 on ClinicalTrials.gov · last registry update 2025-02-07

Closed to new participants; the 50 already enrolled are still being followed. Its estimated completion date, 3 November 2025, has passed with no update to the record. Primary outcome, as filed: Glycemic Control. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is already approved in the US for obesity and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: ACTIVE_NOT_RECRUITING
Phase: P2/P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Durham VA Medical Center
Sponsor type: Fed
Enrollment: 50
Started: 2024-06-24
Primary completion: 2025-11-03 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Glycemic Control

Conditions studied

Type 2 Diabetes · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.